Italy’s biotech sector may not always command the spotlight like its larger European counterparts, yet it is thriving with innovative companies poised to make significant contributions to medical science. The landscape encompasses a diverse array of therapeutic approaches, from gene therapy to protein degradation and neuroscience. Here, we delve into seven Italian biotech firms that are shaping the future of healthcare.
AAVantgarde Bio: Pioneering Gene Therapy
Based in Milan, AAVantgarde Bio focuses on developing gene therapies specifically aimed at inherited retinal disorders. These diseases often result in severe vision impairment or blindness.
The company has devised a dual-AAV approach to tackle a significant technical challenge in ophthalmic gene therapy: many genes linked to retinal diseases are too large to fit into a single adeno-associated virus (AAV) vector. This innovative strategy involves splitting larger genes into two components, which are then reconstituted within target retinal cells to restore function.
AAVB-039, its lead candidate, is currently in a Phase 1/2 clinical trial for treating Stargardt disease, the most prevalent inherited macular degeneration. AAVB-081, another promising program, targets Usher syndrome type 1B, which combines hearing loss with progressive vision loss. In late 2025, AAVantgarde secured $141 million in a Series B funding round, marking a milestone for Italian biotech investments.
Genenta Science: Transforming Tumor Microenvironments
Genenta Science, another Milan-based company, is making strides in cell-based immunotherapy. The firm utilizes autologous hematopoietic stem and progenitor cells (HSPCs) that are genetically modified to express interferon-alpha (IFN-α) in response to tumor-specific signals. This approach allows modified cells to migrate directly to tumors, releasing IFN-α to stimulate anti-tumor immunity while minimizing systemic toxicity.
The lead program, Temferon, is currently being tested in a Phase 1/2 trial for glioblastoma multiforme, a notoriously aggressive brain cancer. Recent interim results showed promising survival rates, with 44% of patients reaching the 18-month mark. However, the company recently announced a strategic pivot towards a broader industrial model, rebranding itself as Saentra Forge, while still pursuing its glioblastoma trial.
Genespire: Advancing Pediatric Gene Therapies
Milan is also home to Genespire, a company developing an innovative platform for off-the-shelf gene therapies targeting pediatric genetic disorders. The Immune-Shielded Lentiviral Vector (ISLV) platform enables the delivery of therapeutic genes directly into liver cells, aiming for sustainable expression from a single administration.
Genespire’s lead candidate, GENE202, focuses on treating methylmalonic acidemia, a severe metabolic disorder. The company recently raised €46.6 million in a Series B round to advance GENE202 into clinical stages and has received Orphan Drug Designation from both the FDA and the European Commission.
IAMA Therapeutics: Neuroscience Innovations
Founded in 2019 as a spin-out from the Italian Institute of Technology, IAMA Therapeutics is dedicated to developing small-molecule therapies for neurodevelopmental and neuropsychiatric disorders. The company’s research centers on restoring chloride homeostasis in neurons, a critical factor in neurotransmission.
IAMA-6, its lead compound, is designed to inhibit the NKCC1 chloride transporter, aiming to rebalance inhibitory signaling in the brain. The candidate has progressed into a Phase 1 human trial, with additional funding secured to support its continued development.
Philogen: Targeting Cancer with Precision
Philogen operates at the intersection of Swiss and Italian biotech, utilizing tumor-targeting antibodies to deliver cytokines directly to cancerous tissues. This innovative approach aims to enhance immune activation at the tumor site while minimizing side effects associated with traditional cytokine therapies.
The company’s prominent candidate, Nidlegy, combines two immunocytokines and is being evaluated in clinical trials for melanoma. Although it faced a setback when the EMA application was withdrawn for additional data, the company continues to advance other promising therapies, including Fibromun for soft-tissue sarcoma and glioblastoma.
Resalis Therapeutics: Reprogramming Metabolic Pathways
Based in Torino, Resalis Therapeutics is developing therapies to reprogram metabolic pathways, with a particular focus on obesity and metabolic-associated fatty liver disease. The lead candidate, RES-010, is an antisense oligonucleotide aimed at inhibiting microRNA-22, which regulates lipid metabolism.
In December 2024, Resalis initiated its first-in-human Phase 1 trial for RES-010, with preliminary results expected in mid-2026. This dual-indication strategy positions the company to address two significant health challenges simultaneously.
Sibylla Biotech: Innovating Protein Degradation
Sibylla Biotech, a startup based near Milan, is pioneering a novel approach to protein degradation. By targeting short-lived protein folding intermediates, the company aims to enhance cellular degradation processes before the proteins become fully functional.
The lead asset, a cyclin D1 degrader, is moving toward clinical trials. Sibylla has also established a collaboration with Ono Pharmaceutical to explore CNS disorders, demonstrating its commitment to expanding its research portfolio.
Conclusion: A Growing Force in Biotech
Italy’s biotech sector, though often overshadowed, is rich with innovation and potential. With a diverse array of companies tackling various medical challenges, the future looks promising. As funding and infrastructure continue to improve, these firms are well-positioned to make a significant impact on global healthcare.
- Italy’s biotech ecosystem is expanding, with nearly 5,900 companies contributing to over €53 billion in turnover.
-
Venture capital investments in biotech reached approximately €357 million in 2025, demonstrating growing investor confidence.
-
The companies highlighted are advancing cutting-edge therapies, from gene treatments to cancer immunotherapies and metabolic health solutions.
Italy’s biotech landscape is poised for a transformation, making it an exciting area to watch in the coming years.
Read more → www.labiotech.eu